What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?

References

• Miller DR. A tribute to Sidney Farber – the father of modern chemotherapy. Br J Haematol. 2006;134:20–26.
   PubMed Web of Science ®Google Scholar
• Cecchino GN, Araujo Junior E, Elito Junior J. Methotrexate for ectopic pregnancy: when and how. Arch Gynecol Obstet. 2014;290:417–423.
   PubMed Web of Science ®Google Scholar
• Pincus T, Sokka T, Cutolo M. The past versus the present, 1980–2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation. 2015;22:89–103.
   PubMed Web of Science ®Google Scholar
• Mahbub MS, Khondker L, Khan SI, et al. Comparative efficacy of hydroxyurea and methotrexate in treating psoriasis. Mymensingh Med J. 2013;22:116–130.
   PubMedGoogle Scholar
• Cairns R, Brown JA, Lynch AM, et al. A decade of Australian methotrexate dosing errors. Med J Aust. 2016;204:384.
   PubMed Web of Science ®Google Scholar
• Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978;3:1–13.
   PubMed Web of Science ®Google Scholar
• Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42:139–151.
   PubMed Web of Science ®Google Scholar
• Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983;43:2342–2345.
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Donsbach RC, Dorick DM, et al. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models. Cancer Res. 1976;36:4672–4678.
   PubMed Web of Science ®Google Scholar
• Schornagel JH, McVie JG. The clinical pharmacology of methotrexate. Cancer Treat Rev. 1983;10:53–75.
   PubMed Web of Science ®Google Scholar
• Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;18:57–63.
   PubMed Web of Science ®Google Scholar
• Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol. 1995;22:1570–1573.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:481–485.
   PubMed Web of Science ®Google Scholar
• Smith DK, Omura GA, Ostroy F. Clinical pharmacology of intermediate-dose oral methotrexate. Cancer Chemother Pharmacol. 1980;4:117–120.
   PubMed Web of Science ®Google Scholar
• Harvey VJ, Slevin ML, Woollard RC, et al. The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. Cancer Chemother Pharmacol. 1984;13:91–94.
   PubMed Web of Science ®Google Scholar
• Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299–3308.
   PubMed Web of Science ®Google Scholar
• Kivity S, Zafrir Y, Loebstein R, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014;13:1109–1113.
   PubMed Web of Science ®Google Scholar
• Serraj K, Federici L, Maloisel F, et al. [Pancytopenia related to low-dose methotrexate: study of five cases and review of the literature]. Rev Med Interne. 2007;28:584–588. French.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Karie S, et al. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol. 2005;64:315–319.
   PubMed Web of Science ®Google Scholar
• Isaacs JD Jr, McGehee RP, Cowan BD. Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: a report of two cases. Obstet Gynecol. 1996;88:694–696.
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909–3915.
   PubMed Web of Science ®Google Scholar
• Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer. 1982;50:869–872.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703.
   PubMed Web of Science ®Google Scholar
• Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41:36–51.
   PubMed Web of Science ®Google Scholar
• Comandone A, Passera R, Boglione A, et al. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol. 2005;44:406–411.
   PubMed Web of Science ®Google Scholar
• Holmboe L, Andersen AM, Morkrid L, et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73:106–114.
   PubMed Web of Science ®Google Scholar
• Cohen IJ, Wolff JE. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer. 2014;61:7–10.
   PubMed Web of Science ®Google Scholar
• Djerassi I, Kim JS. Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin’s lymphomas): parolonged unmaintained remissions. Cancer. 1976;38:1043–1051.
   PubMed Web of Science ®Google Scholar
• Dombrowsky E, Jayaraman B, Narayan M, et al. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011;33:99–107.
   PubMed Web of Science ®Google Scholar
• Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4:87–101.
   PubMed Web of Science ®Google Scholar
• Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer. 1972;8:409–414.
   PubMed Web of Science ®Google Scholar
• Xu W, Tang Y, Song H, et al. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol. 2007;29:688–693.
   PubMed Web of Science ®Google Scholar
• Xu WQ, Zhang LY, Chen XY, et al. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014;73:79–86.
   PubMed Web of Science ®Google Scholar
• Wieferich KSGS, Lynch MJ. Acute oral methotrexate ingestions: a thirteen-year poison center review of acute oral methotrexate exposures. Clin Toxicol. 2014;52:778–779.
   Web of Science ®Google Scholar
• Bebarta VS, Hensley MD, Borys DJ. Acute methotrexate ingestions in adults: a report of serious clinical effects and treatments. J Toxicol. 2014;2014:214574.
   PubMedGoogle Scholar
• LoVecchio F, Katz K, Watts D, et al. Four-year experience with methotrexate exposures. J Med Toxicol. 2008;4:149–150.
   PubMedGoogle Scholar
• Thornton SLRR, Soleymani K, Clark RF, et al. A descriptive study of antineoplastic drug exposures in pediatric patients 5 years old and younger. Clin Toxicol. 2011;49:551.
   Web of Science ®Google Scholar
• Cheung KK, Chow KM, Szeto CC, et al. Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol. 2009;15:177–180.
   PubMed Web of Science ®Google Scholar
• The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid arthritis clinical trial archive group. J Rheumatol. 1995;22:218–223.
   PubMedGoogle Scholar
• Willner N, Storch S, Tadmor T, et al. Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy. Eur J Clin Pharmacol. 2014;70:261–263.
   PubMed Web of Science ®Google Scholar
• Balit CDF, Little M, Murray L. New South Wales Poisons Information Centre. Acute methotrexate overdose. Clin Toxicol. 2006;44:411–412.
   Google Scholar
• Bleyer WA. Therapeutic drug monitoring of methotrexate and other antineoplastic drugs. In: Baer DM, editor. Interpretations in therapeutic drug monitoring. Chicago (IL): American Society of Clinical Pathologists; 1981. p. 169–181.
   Google Scholar
• Tsurusawa M, Gosho M, Mori T, et al. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma. Pediatr Blood Cancer. 2015;62:279–284.
   PubMed Web of Science ®Google Scholar
• Tubiana-Mathieu N, Monjanel-Mouterde S, Lejeune C, et al. Pharmacokinetics of folinic acid and 5-methyltetrahydrofolic metabolite after repeated oral administration of calcium folinate following methotrexate treatment. Eur J Cancer. 1994;30A:1281–1284.
   PubMed Web of Science ®Google Scholar
• Cohen IJ. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol. 2004;26:156–163.
   PubMed Web of Science ®Google Scholar
• Pitman SW, Frei E III. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep. 1977;61:695–701.
   PubMedGoogle Scholar
• Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42:1–26.
   PubMed Web of Science ®Google Scholar
• Christensen AM, Pauley JL, Molinelli AR, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer. 2012;118:4321–4330.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34:427–439.
   PubMed Web of Science ®Google Scholar
• Fermiano M, Bergsbaken J, Kolesar JM. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. Am J Health Syst Pharm. 2014;71:793–798.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28:3979–3986.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004;96:1557–1559.
   PubMed Web of Science ®Google Scholar
• O’Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc. 1996;71:161–165.
   PubMed Web of Science ®Google Scholar
• Bradley AM, Buie LW, Kuykendal A, et al. Successful use of intrathecal carboxypeptidase G2 for intrathecal methotrexate overdose: a case study and review of the literature. Clin Lymphoma Myeloma Leuk. 2013;13:166–170.
   PubMed Web of Science ®Google Scholar
• Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987;110:788–792.
   PubMed Web of Science ®Google Scholar
• Tukova J, Chladek J, Nemcova D, et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009;27:1047–1053.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645–648.
   PubMed Web of Science ®Google Scholar
• Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845–1849.
   PubMed Web of Science ®Google Scholar
• Campbell MA, Perrier DG, Dorr RT, et al. Methotrexate: bioavailability and pharmacokinetics. Cancer Treat Rep. 1985;69:833–838.
   PubMedGoogle Scholar
• Stuart JF, Calman KC, Watters J, et al. Bioavailability of methotrexate: implications for clinical use. Cancer Chemother Pharmacol. 1979;3:239–241.
   PubMed Web of Science ®Google Scholar
• Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from children’s oncology group study AALL0232. J Clin Oncol. 2016;34:2380–2388.
   PubMed Web of Science ®Google Scholar
• Zelcer S, Kellick M, Wexler LH, et al. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer. 2008;50:1176–1180.
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Barisone E, Vivalda M, et al. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma]. Minerva Pediatr. 1996;48:193–200. Italian.
   PubMedGoogle Scholar
• Leahy MF, Silver HK, Klimo P, et al. Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue. Med Pediatr Oncol. 1982;10:151–156.
   PubMedGoogle Scholar
• Kirkwood JM, Canellos GP, Ervin TJ, et al. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981;47:2414–2421.
   PubMed Web of Science ®Google Scholar
• Isacoff WH, Townsend CM, Eiber FR, et al. High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. Med Pediatr Oncol. 1976;2:319–325.
   PubMedGoogle Scholar
• Lucchesi M, Guidi M, Fonte C, et al. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. Cancer Chemother Pharmacol. 2016;77:857–864.
   PubMed Web of Science ®Google Scholar